ARCHIVES

SEC Investigating Bristol-Myers’ Sales Statements

This article is from The Cancer Letter archive.

Vol. 28 No. 28 | July 12, 2002

Download PDF Visit The Full Archive

Related Articles

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

Prevention & Control Study Section In DRG Requested By NCI

February 8, 1991

Colorectal Cancer Screening Practices Need Improvement, CDC Practice Study Finds

April 30, 2010

FDA Approves DNA Test For Two Types of HPV

March 27, 2009

Contract For NCI CIS Service Center Awarded To Fred Hutchinson

December 11, 2009

Abraxane and Gemcitabine Improves Overall Survival

November 30, 2012